ClinicalTrials.gg
CompletedNCT04947553ACCORD-2Updated Dec 8, 2025

A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation

A Phase 3 interventional study of AXS-05 (dextromethorphan-bupropion) and Placebo in Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease and Agitation, Psychomotor, sponsored by Axsome Therapeutics, Inc.. Completed at 47 sites in 3 countries. Open to participants aged 65 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2024, 1 year 11 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Dec 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
456
Allocation
Randomized
Ages
65 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
198th of 1,609
456 · median 73
Started
2021
with 144 others
Phase 3
188 of 1,940
19 open now
Registered
1,341st of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 198th largest by enrollment of the 1,609 interventional ones that give a count, is one of 145 that started in 2021, is one of 188 in phase 3, and was the 1,341st registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 65 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the long-term safety and efficacy of AXS-05 in subjects with Alzheimer's disease (AD) agitation.

Read the detailed description

This study is a multi-center trial consisting of an open-label segment of up to 52 weeks, followed by a double-blind, placebo-controlled, randomized withdrawal segment. Subjects participating in the randomized-withdrawal segment will be randomized in a 1:1 ratio either to continue to receive AXS-05 or switch to placebo, for up to 24 weeks.

03

Conditions studied

  • Agitation in Patients With Dementia of the Alzheimer's Type
  • Alzheimer Disease
  • Agitation, Psychomotor

Keywords

  • AD agitation
  • AXS-05
  • NMDA receptor antagonist
  • dextromethorphan
  • bupropion
  • Axsome
04

Who can participate

Ages eligible
65 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participation in Study AXS-05-AD-302 or Study AXS-05-AD-304.
  • Caregiver is willing to communicate with site personnel, comply with all required study procedures, and oversee administration and compliance with the subject's study treatment.

Exclusion criteria

Exclusion Criteria:

  • Caregiver is unwilling or unable, in the opinion of the investigator, to comply with study instructions.
  • Subject is hospitalized in a mental health facility (e.g., psychiatric hospital or ward), living in a nursing home, or living alone.
  • Any concurrent medical condition that might interfere with the conduct of the study, confound the interpretation of study results, or endanger the subject's well-being.
  • Initiation of a new medication since enrolling in AXS-05-AD-302 or AXS-05-AD-304 which may pose a safety risk when taken concurrently with AXS-05.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
456 participants (actual)

Study arms

  • Experimental
    AXS-05 (dextromethorphan-bupropion)

    * Up to 52 weeks in the open-label segment; * Up to 24 weeks in the randomized double-blind segment (if applicable)

    Drug: AXS-05 (dextromethorphan-bupropion)

  • Placebo comparator
    Placebo

    Up to 24 weeks in the randomized double-blind segment (if applicable)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Long-term Safety

    Incidence of treatment-emergent adverse events following dosing with AXS-05

    Time frame: up to 76 weeks

  2. Time to relapse of agitation symptoms

    Time frame: up to 24 weeks

Other outcomes

  1. Cohen-Mansfield Agitation Inventory (CMAI)

    Change from Baseline to last dose in the CMAI

    Time frame: up to 76 weeks

07

Study locations

47 sites
  • Clinical Research Site
    Peoria, Arizona 83581, United States
  • Clinical Research Site
    Tempe, Arizona 85282, United States
  • Clinical Research Site
    Long Beach, California 90807, United States
  • Clinical Research Site
    Santa Ana, California 92705, United States
  • Clinical Research Site
    Temecula, California 92591, United States
  • Clinical Research Site
    Walnut Creek, California 94596, United States
  • Clinical Research Site
    Bonita Springs, Florida 34134, United States
  • Clinical Research Site
    Brandon, Florida 33511, United States
  • Clinical Research Site
    Coral Springs, Florida 33067, United States
  • Clinical Research Site
    Greenacres City, Florida 33467, United States
  • Clinical Research Site
    Hialeah, Florida 33012, United States
  • Clinical Research Site
    Hollywood, Florida 33024, United States
  • Clinical Research Site
    Kissimmee, Florida 34741, United States
  • Clinical Research Site
    Lake City, Florida 32055, United States
  • Clinical Research Site
    Miami, Florida 33126, United States
  • Clinical Research Site
    Miami, Florida 33135, United States
  • Clinical Research Site
    Miami, Florida 33145, United States
  • Clinical Research Site
    Miami, Florida 33155, United States
  • Clinical Research Site
    Miami, Florida 33165, United States
  • Clinical Research Site
    Miami, Florida 33173, United States
  • Clinical Research Site
    Miami, Florida 33175, United States
  • Clinical Research Site
    Miami Gardens, Florida 33014, United States
  • Clinical Research Site
    Miami Lakes, Florida 33014, United States
  • Clinical Research Site
    Orlando, Florida 32807, United States
  • Clinical Research Site
    Pembroke Pines, Florida 33025, United States
  • Clinical Research Site
    Tampa, Florida 33614, United States
  • Clinical Research Site
    Tampa, Florida 33634, United States
  • Clinical Research Site
    Trinity, Florida 34655, United States
  • Clinical Research Site
    Columbus, Georgia 31909, United States
  • Clinical Research Site
    Wichita, Kansas 67214, United States
  • Clinical Research Site
    Braintree, Massachusetts 02184, United States
  • Clinical Research Site
    Flint, Michigan 48532, United States
  • Clinical Research Site
    Rochester Hills, Michigan 48307, United States
  • Clinical Research Site
    Chesterfield, Missouri 63005, United States
  • Clinical Research Site
    Toms River, New Jersey 08755, United States
  • Clinical Research Site
    Brooklyn, New York 11229, United States
  • Clinical Research Site
    New Windsor, New York 12553, United States
  • Clinical Research Site
    Staten Island, New York 10314, United States
  • Clinical Research Site
    Charlotte, North Carolina 28211, United States
  • Clinical Research Site
    Hickory, North Carolina 28601, United States
  • Clinical Research Site
    Austin, Texas 78737, United States
  • Clinical Research Site
    Cypress, Texas 77429, United States
  • Clinical Research Site
    Mesquite, Texas 75149, United States
  • Clinical Research Site
    Sugar Land, Texas 77478, United States
  • Clinical Research Site
    Arlington, Virginia 22205, United States
  • Clinical Research Site
    Kelowna, British Columbia V1Y 1Z9, Canada
  • Clinical Research Site
    San Juan, 00918, Puerto Rico
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Dec 2024, 41 months.

Of 75 industry-sponsored phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 41 months is close to that.

Counting every sponsor, half of 101 studies reached it within 47 months; a quarter within 28 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2021
First posted
Jul 1, 2021
StartActual
Jun 17, 2021
Primary completionActual
Dec 3, 2024
CompletionActual
Dec 21, 2024
Results delay requested
Dec 3, 2025
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04947553
Responsible party
Sponsor
First posted
Jul 1, 2021
Start date
Jun 17, 2021
Primary completion
Dec 3, 2024
Completion
Dec 21, 2024
Last update
Dec 8, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dextromethorphan/Bupropion Tablet AXS-05

Start the discussion